文献速递帕金森病与运动障碍

跨祖源帕金森病遗传学:致病与风险变异的观察性遗传研究

Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications.
PubMed 文献 · Lancet Neurol · 2026-01-01

约29%来自非欧洲和非德系犹太人群体;

要点

  • GBA1风险变异最常见且见于所有祖源,频率谱差异大。
  • LRRK2致病变异在德系犹太人和中东祖源富集。

核心结论

  • 帕金森病遗传结构存在祖源特异性差异,增加祖源多样性对精准诊疗和公平获取基因导向治疗至关重要。

研究设计与样本

  • 多祖源、观察性、横断面遗传研究,使用GP2 release 11回顾性数据。
  • 纳入99 783人(58 559例帕金森病、41 224对照),来自11个遗传推断祖源。

关键数值与推荐

  • 帕金森病诊断基于Parkinson's UK Brain Bank或MDS诊断标准(或两者)。
  • 健康对照定义为无神经退行性疾病证据且与帕金森病患者无亲缘关系。

临床怎么用

  • 临床解读帕金森病遗传变异时应考虑患者祖源背景,避免欧洲中心阈值直接外推。
  • 对GBA1和LRRK2变异携带者的临床试验入组和基因导向治疗需关注祖源多样性。
  • 在非欧洲人群中开展遗传检测有助于提高诊断准确性并理解疾病机制。

局限性

  • 研究为观察性横断面设计,无法推断因果或临床结局。
  • 仅报告等位基因频率,未报告外显率、年龄依赖性或基因型-表型关联。
  • 祖源推断基于参考人群方法,可能无法完全反映个体遗传背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The genetic architecture of Parkinson's disease varies considerably across ancestries, yet most previous genetic studies have focused on individuals of European ancestry. We aimed to characterise the distribution of established Parkinson's disease causal variants, as well as risk-associated variants with clinical implications (ie, variants in genes involved in pathways targeted by ongoing clinical trials), across ancestrally diverse populations. METHODS: We conducted a multi-ancestry, observational, cross-sectional genetic study using retrospective data from the Global Parkinson's Genetics Program (GP2) release 11 (released in December, 2025). The study investigated causal and risk variants, including copy number variants, in established Parkinson's disease and parkinsonism-associated genes, following the recommendations of the Movement Disorder Society (MDS) Task Force on the Nomenclature of Genetic Movement Disorders, including GBA1, LRRK2, SNCA, VPS35, RAB32, PINK1, PRKN, PARK7, ATP13A2, DCTN1, DNAJC6, FBXO7, JAM2, RAB39B, SLC20A2, SYNJ1, VPS13C, and WDR45. Individuals with Parkinson's disease were diagnosed based on established clinical criteria, including the Parkinson's UK Brain Bank or MDS diagnostic criteria (or both), and healthy control participants were defined as individuals without evidence of neurodegenerative disease and unrelated to participants with Parkinson's disease. We analysed genome and exome sequencing and array genotyping data of 99 783 individuals, including 58 559 individuals with Parkinson's disease and 41 224 controls, from 11 genetically inferred ancestries (African, African admixed, Ashkenazi Jewish, Latino and Indigenous people of the Americas, central Asian, complex admixture, east Asian, European, Finnish, Middle Eastern, and south Asian), defined using reference population-based ancestry inference methods. We calculated allele frequencies for all investigated variants in individuals with Parkinson's disease and controls, both overall and stratified by ancestry. FINDINGS: Approximately 29% of individuals (29 001 of 99 783; 15 443 [26·4%] of 58 559 individuals with Parkinson's disease and 13 558 [32·9%] of 41 224 controls) were from under-represented populations (ie, non-European and non-Ashkenazi Jewish). Our findings indicated both shared genetic contributors across ancestries as well as ancestry-specific differences in variant frequencies and the spectrum of variants within Parkinson's disease-associated genes. Overall, 1217 (2·1%) of 58 559 individuals with Parkinson's disease carried a causal variant, with substantial variations across ancestries ranging from ten (0·4%) of 2844 African individuals to 251 (10·7%) of 2343 individuals of Ashkenazi Jewish ancestry. Risk variants in GBA1 and LRRK2 were identified in 6893 (11·8%) of 58 559 individuals with Parkinson's disease and 3578 (8·7%) of 41 224 controls. GBA1 risk variants were most frequent overall and identified across all ancestries, but variant frequency and spectra differed substantially between ancestries, from 195 (4·1%) of 4773 in the east Asian ancestry group to 1505 (52·9%) of 2844 in the African ancestry group. Similarly, LRRK2 causal and risk variants showed ancestry-specific enrichment, with the highest frequencies of causal variants in the Ashkenazi Jewish (250 [10·7%] of 2343) and Middle Eastern (59 [4·4%] of 1347) ancestry groups, whereas risk variants were predominantly identified in the east Asian ancestry group (601 [12·6%] of 4773). Carriers of biallelic causal variants in PRKN, commonly including deletions and duplications, were also identified across all ancestries except Ashkenazi Jewish; the highest frequency was in the Middle Eastern ancestry group (17 [1·3%] of 1347), and frequencies in all other ancestries were less than 1%. INTERPRETATION: This large-scale, multi-ancestry genetic study offers crucial insights into the population-specific genetic architecture of Parkinson's disease. Whereas clinical trials targeting GBA1 and LRRK2 variant carriers are primarily performed in Europe and the USA, increased ancestral diversity in Parkinson's disease research will be crucial to improve diagnostic accuracy, enhance our understanding of disease mechanisms across populations, and ensure equitable application of and access to emerging genetically informed therapies. FUNDING: Aligning Science Across Parkinson's (ASAP) through the Global Parkinson's Genetics Program (GP2).

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Lange LM, Fang ZH, Makarious MB, et al. Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications. Lancet Neurol. 2026. PMID: 42456684. doi:10.1016/S1474-4422(26)00198-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。